CMAX is Australia’s longest established, independent facility for clinical trials and delivers exceptional quality, meeting all international regulatory requirements. Since 1993 we have designed and delivered more than 600 early phase clinical trials, including more than 100 first in human studies for our clients including pharmaceutical, biotechnology and device companies.
Our modern, custom-built facility opened in 2016 opposite the Royal Adelaide Hospital and next to Adelaide’s Bio-Med City, one of the largest health and life sciences clusters in the southern hemisphere. Bio-Med City provides ready access to state-of-the-art facilities, equipment and world-class medical and pharmacology specialists and CMAX holds long-established relationships with medical specialists across all of these institutions.
At CMAX our expert team supports our global client base to accelerate quality product development in Phase I-II studies, as well as later phases, delivering exceptional service.
We operate in a wide range of therapeutic areas and have experience in most routes of study drug administration and variety of investigational compounds encompassing NCEs, small molecules, monoclonal antibodies, vaccines, gene therapy and biosimilars.
Find out how we can tailor our expertise, clinical trial services and research capabilities to provide you added value at every stage of your research project.
Since 1993, CMAX has partnered with local and international research organisations to deliver a range of end-to-end services for clinical trials.
Many of CMAX sponsors are located internationally, including the USA, Asia, Japan, Taiwan and Europe.
Testimonial from a CMAX customer
“When we were searching for a Phase 1 clinic we quickly closed in on the city of Adelaide, Australia. The support of the ethics committee review and the R&D tax rebate reimbursement were a great support. We found that Adelaide offered us access to a number of experts, including CMAX.
It’s quite unique for government agencies like Health Industries South Australia to be so accessible but they were very ready to help smaller companies like InCarta who want to expand their R&D in Australia ”
Chief Operating Officer and Co-Founder, InCarda Therapeutics Inc